There is a reevaluation of corticosteroid use in metastatic hormone-sensitive prostate cancer. However, reports also mention reexaminations in other areas of oncology, including the use of next-generation cdK inhibitors in metastatic breast cancer and the consumption of soyfoods by breast cancer patients. The scope of the reevaluation appears to be broader than just one specific cancer treatment.